The Zhitong Finance App learned that in June of this year, Mr. Wu, a Taiwanese businessman who has been suffering from Parkinson's disease for 13 years, came to Hangzhou to receive personalized and precise brain circuit stimulation treatment at Shulan (Hangzhou) Hospital, a subsidiary of Shulan Medical Group. After completing the full course of treatment, Mr. Wu's physical condition improved markedly, and he made a special trip to West Lake.
When looking from individuals to a wider group, a representative question arises: how to break through the bottlenecks of traditional standardized diagnosis and treatment in the face of highly complex brain diseases with huge individual differences? What kind of core carriers and system capabilities are needed for cutting-edge technology to move towards large-scale clinical application?
The “National Demonstration Center for Neural Regulation and Precise Targeted Therapy”, jointly built by Shulan Medical Group and Galaxy Brain Science, provides a window for observation.
Draw a different “brain map” for everyone
The human brain is not a “standard part” made according to uniform drawings. With the same disease, there may also be differences in the location, boundaries, and ways in which the functional networks of the brain are connected in different patients. If we only rely on group average maps to find stimulation targets, there are natural boundaries in the degree of accuracy.
The “National Demonstration Center for Neural Regulation and Precise Targeted Therapy”, jointly built by Shulan Medical and Galaxy Brain Science, aims to solve this precision medicine problem through individualized treatment plans, starting with individual differences and relying on functional magnetic resonance imaging (fMRI) and individual brain function segmentation (PBFs) techniques.
From an industry perspective, this path shifts treatment from “finding experience points” to “finding data points,” and moving from “treating the same disease with the same disease” to “treating the same disease differently.”
Research continues to answer “why” and “how to do it”. What really determines whether a technology can change from research results to medical services is whether it can enter the real world diagnosis and treatment system and operate stably. This is also the value of cooperation between Shulan Medical and Galaxy Brain Science and other professional technology companies to push technology from laboratory to clinical.
The real threshold for landing is more than just a device
When a technology actually enters the medical scene, the challenge is far more complicated than “buying a device”: the technical effects in the laboratory still need further verification after entering the actual clinical scenario.
In 2025, Shulan Medical and Galaxy Brain Science jointly established the “National Neuromodulation and Precise Targeted Therapy Demonstration Center”. The two sides collaborated to build a closed loop of innovative diagnosis and treatment throughout the “Accurate Assessment - Targeted Control - Long-term Management” to improve patients' diagnosis and treatment experience and provide a reusable framework for large-scale application of technology.
In addition to process standardization, data governance is another threshold for technology implementation. The use of relevant images and clinical data must be carried out on the premise that it complies with regulations and ethics, and data masking and authority supervision are indispensable. For a technology-based medical group like Shulan Medical, these seemingly non-technical aspects are essential basic capabilities for the implementation of technology.
From running through the process from one hospital area to forming a relatively consistent diagnosis and treatment path across multiple hospitals, medical groups are required to have not only high-quality medical core capabilities, but also standardized system capabilities in clinical process restructuring, multidisciplinary collaboration, and large-scale replication.
One question worth asking is: Why would this kind of cooperation be implemented in a social medical enterprise?
Social medical enterprises are generally relatively flexible. Corporate operations provide an organizational carrier for cross-regional replication of technology, and can become a hub for scientific and technological clinical transformation. As part of the community's medical practice, Shulan Healthcare's scientific and technological strategy takes into account independent research and development and open cooperation, introduces partners with open thinking, provides clinical scenarios and multidisciplinary teams, and carries out data collaboration under the premise of compliance; partners such as Galaxy Brain Science provide technology and solutions, forming a complementary cooperation paradigm of “technology supply+scenario acceptance”. This model can be seen as a sample of social medical forces participating in the construction of a national medical science and technology innovation system and implementing policies to transform scientific and technological achievements.
The logic of technological growth behind a “leaf”
Taking the perspective farther, the National Neuromodulation and Precise Targeted Treatment Demonstration Center is more like a leaf of Shulan's medical technology layout. To understand this “leaf,” you need to put it in a whole.
In recent years, expressions such as computational medicine, artificial intelligence, transformation of scientific research results, and full-life cycle health management have appeared more and more frequently in Shulan Medical's strategic narratives. The proposed “two-wheel drive” strategy clearly points: on the one hand, continue to develop high-quality medical services; on the other hand, cultivate new space for growth through scientific and technological innovation and industrial transformation, and respond to the country's “innovation-driven development” strategy.
In 2025, Shulan Medical announced an “All in Technology” strategy upgrade. Zheng Jie, founder and president of the group, proposed using computational medicine to build a future medical model: using data as the core production factor, integrating multi-scale life mechanism modeling, statistical learning and high-performance computing, and establishing a new medical logic of “self-developed system - data driven - AI enabled” to push medicine from “seeing a doctor” to “counting diseases.”
The demonstration center just implemented this grand logic into an actual sample. Clinical data is generated, and doctors formulate personalized and accurate treatment plans with the assistance of cutting-edge technology; in-hospital surgical research projects promote the output of better research results under the premise of complying with regulations and ethics, thus forming a positive feedback cycle of “asking questions clinically - seeking answers through technology - completing the transformation of hospitals”. Shulan Medical undertakes technological innovation with clinical scenarios, providing a “last mile” channel from laboratory to clinical research results.
Judging from industry trends, China's social medical services are in a transition period from scale expansion to quality improvement. As the reform of China's medical and health services continues to deepen, differentiated technical capabilities and service capabilities have become a new competitive dimension. Shulan Medical chose computational medicine as the core. Essentially, it establishes advantages in the rapid transformation of scientific and technological achievements through differentiated positioning: hospitals are not only places to provide medical services, but also testing grounds and incubators for scientific and technological innovation; undertakes technological innovation with clinical scenarios, is driven by computational medicine, and uses open cooperation as a mechanism to establish an ecological cycle of innovation and return.
Judging from business logic, its core value is “reuse.” Concepts represented by computational medicine help promote and apply proven technologies and processes, so that clinical experience and technical solutions can be reused across regions and disciplines. This non-linear growth potential is the key to a technology-based healthcare group.
Today, new quality productivity has become a key variable for the high-quality development of the healthcare industry. As technological capabilities gradually become the core growth engine, China's emerging social medical forces, represented by Shulan Healthcare, are exploring another possibility.